PreclinicalShort bioregulator peptide

Chonluten

Glu-Asp-Gly (EDG), Honluten

Common dose: 0.2–10 mg daily for 10–20 days
Cycle: 2-week course, about every 4 months
Vial sizes: 20 mg
Typical draw: 10 units20 mg with 2 mL, 1 mg

A synthetic three-amino-acid peptide from the Russian bioregulator family, linked by its developers to the bronchial lining and sold for lung and airway support. Its only published study found anti-inflammatory effects in immune cells in a dish.

Evidence. One cell-line study from an Italian lab working with Khavinson’s institute, plus computer modeling. Despite its marketing for the lungs, no animal or human study naming Chonluten or its sequence has been published.

What it’s used for

None of these uses is approved, and none has been tested in people. Here is what each claim rests on.

Bronchitis and COPD: No studyUnproven: sold for the bronchi and lungs, but no animal or human study of Chonluten in any lung disease has been published.
Inflammation: AnimalIn a 2022 Italian lab study, human immune cells in a dish released less of the inflammatory signal TNF after a bacterial trigger; with related peptides, IL-6 also fell. Not tested in animals or people.
Recovery after COVID-19 or pneumonia: No studySome guides promote it after COVID-19, but no study has tested it for COVID-19, pneumonia or recovery from either.
Joint and cartilage health: No studySome sellers market it for joints, apparently confusing it with cartilage peptides such as Cartalax; no study links it to joints.

Animal: cell or animal studies only. No study: nothing published supports it.

Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.

Status

Approval: Not approved as a drug in the US or EU. In Russia it’s sold as oral capsules marketed as a dietary supplement, not as a medicine.
US compounding: Not nominated for US compounding: it isn’t on FDA’s 503A (May 2026) or 503B (March 2025) bulk substance nomination lists.
European Union: No marketing authorization; no medicine containing Chonluten is approved anywhere.
United Kingdom: No marketing authorization (MHRA).
Canada: No marketing authorization; no Chonluten product is listed in Health Canada’s Drug Product Database.
Australia: No marketing authorization. Chonluten isn’t named in the Poisons Standard (October 2026).
Sport (WADA 2026): Likely banned in sportNot named on WADA’s 2026 list. A supplement sale isn’t an approval for human therapeutic use, so its S0 rule for non-approved substances likely applies, at all times.

Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.

How it works

No receptor or target is known. In its only published study (Italy, 2022), human immune cells (THP-1 monocytes) exposed overnight to this three-amino-acid peptide released less TNF, an inflammatory signal, after a bacterial trigger; with four related Khavinson peptides it also lowered IL-6 and made the cells stick less to blood-vessel lining cells. Computer modeling suggests it fits transporters that carry small peptides into cells.

AnimalMainly from cell and animal studies; not shown in people.

Not known

Nothing is known about what reaches the lungs after a capsule or injection, whether the cell findings happen in animals or people, or about any target in airway tissue.

Protocol

Community

Injected: guides split between 200–250 mcg and 5–10 mg once daily for 10–20 days, about a 50-fold spread. None was tested in people.

Community

By mouth: guides list 10–20 mg a day for 10–20 days, and Russian supplement capsules are sold. No human study has tested either.

Frequency: Once daily during a course
Route: Subcutaneous injection or capsules by mouth (community)
Cycle: 10–20 day courses, every 3–6 months.
2-week course, about every 4 months, shown over 26 weeks

Common protocols

The ways Chonluten is most often run, each tagged with where it comes from.

Low-dose injected course

Community

Dose: 200–250 mcg
How often: Once daily
How long: 10 days

Some guides; one repeats it every 4–6 months. Untested in people.

Draw 2–2.5 units20 mg + 2 mL

Milligram injected course

Community

Dose: 5–10 mg
How often: Once daily
How long: 10–20 days

Other guides, repeated every 3–6 months. Also untested.

Draw 50–100 units20 mg + 2 mL

Capsule course

Community

Dose: 10–20 mg, or Russian supplement capsules
How often: Once daily
How long: 10–20 days

Repeated 2–3 times a year in guides. No human study has used the capsules.

Taking it

Where it goes

Subcutaneous, rotating between the abdomen, thigh and upper arm; capsules are swallowed. The only published study used cells in a dish.

If you miss a dose

No published guidance. Resume the next day and don’t double up.

Missed doses for every compound

What to expect

During a course
Guides claim easier breathing and airway support. No animal or human study has measured any effect.
Community
Overnight (cells)
In human immune cells in a dish, overnight exposure cut the release of TNF, an inflammatory signal, after a bacterial trigger.
Animal

Side effects and what to do

Injection-site redness or swelling

Usually mild; rotate sites. Spreading redness, heat or pus means see a doctor.

No side-effect data from people

No study has given it to anyone, so side effects and their rates are unknown.

Allergic reaction (possible with any injected peptide)

Stop and get emergency care for hives, facial swelling or trouble breathing.

Stop and get medical help

Stop and get medical help for hives, swelling of the face or throat, trouble breathing, or a hot, spreading or pus-filled injection site.

Can it cause …?

There are almost no human safety data for Chonluten, so most of these can’t be answered either way.

Cancer risk: PrecautionUnknown. In a leukemia-derived cell line, it and related peptides raised growth signals and growth rate; no study has tested its effect on tumors.
TirednessHeadacheNausea or vomitingDiarrhea or constipationDizzinessTrouble sleepingHair lossAcne, rash or skin changesWater retention or swellingJoint or muscle painAnxiety, low mood or irritabilityLow or high blood sugarFast heartbeat or blood pressure changesMore hungerLiver strainKidney problems: No dataNo human data: no study of Chonluten in people has been published, so side effects are unknown.

Precaution: a concern that follows from how it works or from a related drug, not measured. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.

Who should avoid it

No product label covers Chonluten, so these come from human studies and from precautions based on how it works. Most important first.

Anyone with active or past cancer: PrecautionIn a leukemia-derived cell line, it and related peptides raised growth signals and growth rate. No study has tested its effect on tumors.
Pregnancy or breastfeeding: PrecautionNo human safety data exist.
Asthma, COPD or other lung disease: PrecautionSold for the lungs but never tested in lung disease, in animals or people; no evidence supports using it in place of standard treatment.
Anyone relying on product quality: PrecautionIt isn’t an approved drug anywhere, so vials have no regulated standard for identity, purity or sterility, and guides and sellers list several wrong sequences.

Interactions

No interaction studies have been published, and no product label lists any.

Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.

Special situations

What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.

Pregnancy: PrecautionNo human or animal pregnancy data, so effects on a pregnancy are unknown.
Breastfeeding: PrecautionNo human data; it isn’t known whether it passes into breast milk.
Kidney problems: PrecautionNot studied in people with kidney disease; how the body clears it is unknown.
Liver problems: PrecautionNot studied in people with liver disease; how the body breaks it down is unknown.
Older adults: PrecautionNo published study in older people, or in animals of any age.
Children and teens: PrecautionNot studied in anyone under 18, and not approved for any age.
Surgery and anesthesia: PrecautionNo data; tell the surgical team about any injected compound.

Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.

Human studies

No published human studies of Chonluten turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

Trials under way

No ongoing trial of Chonluten is registered, and none has finished recently without publishing its results. Checked on ClinicalTrials.gov, October 7, 2026. Every compound: trials under way.

Limits of the evidence

No study has given Chonluten to animals or people. Its published record is one 2022 cell study from an Italian lab working with Khavinson’s institute, which tested it alongside four related peptides in a leukemia-derived immune cell line, plus computer modeling. The lung and airway claims rest on its developers’ naming, not on data. Doses, safety and product purity are untested.

Mixing your vial

Vial	Water	Common dose	Draw	Strength	Action
20 mg	2 mL	1 mg	10 units (0.10 mL)	10 mg/mL

20 mg in 2 mL gives 10 mg per mL, so 1 mg is 10 units on a U-100 syringe; 200 mcg doses need more water, and 10 mg fills a 1 mL syringe. In Russia it’s also sold as oral capsules, which need no mixing.

Dose chart

20 mg vial

Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.

Dose	Water added
Dose	1 mL	2 mL	3 mL
0.2 mg
0.4 mg
0.6 mg
1 mg
1.5 mg
3 mg
5 mg
10 mg

U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.

Datasheet

Half-life: No reliable value has been published.
Type: Peptide, 3 amino acids
Molecular weight: 319.3 g/mol
Formula: C₁₁H₁₇N₃O₈
Sequence: EDG
Storage before use: Freezer (about −20 °C) for long-term storage.
After mixing or opening: Fridge (2–8 °C); use within about 4 weeks.

Molecule: PubChem CID 194641 (Glu-Asp-Gly); named Chonluten in Avolio et al., Int J Mol Sci 2022
Storage: Community Common practice for research peptides; no approved label exists.

Every compound side by side: the half-life chart and the storage chart.

Identifiers

CAS number: 75007-24-8 (as listed in PubChem)
UNII (FDA): None assigned
PubChem CID: 194641
ATC code: None assigned
Development codes: None; also written EDG (Glu-Asp-Gly) or Honluten; listed as T-34 tripeptide in PubChem
Brand names: None as a medicine; Chonluten is the name of Russian supplement capsules
First described: From Khavinson’s St Petersburg group; the first PubMed record naming it is a 2022 Italian cell study.

Every compound’s numbers: the identifiers table.

Product form and quality

A three-amino-acid peptide, Glu-Asp-Gly (EDG), sold as Russian supplement capsules and research vials. Guides and sellers also list wrong sequences, including Cartalax’s Ala-Glu-Asp, and some market it for joints. A certificate of analysis should show a mass near 319.

Cautions

No animal or human study of Chonluten has been published; the only study used cells in a dish.
Guides and sellers list several wrong sequences, and doses differ about 50-fold.
Not a cartilage or joint peptide, despite some sellers’ claims.

Questions

What is Chonluten?

How does Chonluten work?

Is Chonluten FDA-approved?

Not approved as a drug in the US or EU. In Russia it’s sold as oral capsules marketed as a dietary supplement, not as a medicine. Not nominated for US compounding: it isn’t on FDA’s 503A (May 2026) or 503B (March 2025) bulk substance nomination lists.

What is the usual Chonluten dose?

From community reports, not established: Injected: guides split between 200–250 mcg and 5–10 mg once daily for 10–20 days, about a 50-fold spread. None was tested in people. By mouth: guides list 10–20 mg a day for 10–20 days, and Russian supplement capsules are sold. No human study has tested either. These are the amounts sources reference, not recommendations.

How much water do I mix Chonluten with?

There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 20 mg vial, the strength is 10 mg/mL, so 1 mg is 10 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.

Who should avoid Chonluten?

No product label covers Chonluten, so these come from human studies and from precautions based on how it works. Anyone with active or past cancer: In a leukemia-derived cell line, it and related peptides raised growth signals and growth rate. No study has tested its effect on tumors. Pregnancy or breastfeeding: No human safety data exist. Asthma, COPD or other lung disease: Sold for the lungs but never tested in lung disease, in animals or people; no evidence supports using it in place of standard treatment. The “Who should avoid it” section lists 1 more group.

How should Chonluten be stored?

Before mixing: Freezer (about −20 °C) for long-term storage. After mixing: Fridge (2–8 °C); use within about 4 weeks. This is common practice; no product label covers it.

Is Chonluten banned in sport?

Probably. Not named on WADA’s 2026 list. A supplement sale isn’t an approval for human therapeutic use, so its S0 rule for non-approved substances likely applies, at all times.

Has Chonluten been studied in people?

No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.

How long has Chonluten been studied in people?

No data No human studies: no study of Chonluten in people has been published.

Does Chonluten come in other forms, like a pill or nasal spray?

No data No human data for any route. In Russia it’s sold as capsules to swallow, and research vials are injected under the skin. The only published study used it on cells in a dish.

Can you drink alcohol while taking Chonluten?

No study No data. No study has looked at Chonluten and alcohol together.

Can Chonluten be taken with semaglutide or tirzepatide?

No study No study has combined them. No interaction is known, but none has been looked for.

What happens if you take too much Chonluten?

No data There’s no label, no overdose data and no human dosing study. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.

Sources

Avolio et al., five Khavinson peptides, including Chonluten (Glu-Asp-Gly), on inflammation in human monocyte cells (Int J Mol Sci 2022) PMID 35408963
Khavinson et al., computer docking of 26 short peptides, including EDG, to amino acid and peptide transporters (Biomolecules 2023) PMID 36979488

For uses, the side-effect questions, special situations, trials, identifiers and status outside the US

ClinicalTrials.gov search for Chonluten and Honluten (October 8, 2026)
FDA Global Substance Registration System search (no record) and PubChem CID 194641
Health Canada Drug Product Database search (October 8, 2026) and Australian Poisons Standard, October 2026 (F2026L01327)

Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.

By Vial Guide editorsLast reviewed October 7, 2026

How we review